Code Biotherapeutics
Pioneering Targeted Delivery of Genetic Medicines
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- codebiotx.com
- Total Funding
- $85.0M
- Last Round
- $75.0M Series AJun 2022
About
Code Biotherapeutics is a preclinical-stage genetic medicine company developing transformational non-viral delivery of genetic medicines using its proprietary 3DNA® platform. The 3DNA platform is a multivalent synthetic DNA scaffold engineered to overcome key challenges in genetic medicine delivery including dose-related toxicity and immunogenicity. Code Bio's most advanced program targets Duchenne Muscular Dystrophy.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account